Disease-modifying antirheumatic drug selection in Japanese patients with rheumatoid arthritis treated with biologics or JAK inhibitors without methotrexate: A retrospective hospital-based administrative claims database study
Modern Rheumatology · 2024
DOI: 10.1093/mr/roae021 ↗Kurz gefasst
Fachartikel in der Zeitschrift Modern Rheumatology, 2024. Verfasst von Naohisa Miyakawa und 3 weiteren Autor:innen. Beteiligte Einrichtung: Japan Medical, Innovative Medicine, Bristol Myers Squibb K.K., Tokyo, Japan. Hauptthemen laut MEDLINE: Arthritis, Rheumatoid, Antirheumatic Agents, Methotrexate, Janus Kinase Inhibitors. Die Arbeit nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Objectives
We evaluated the medication selection and clinical characteristics of rheumatoid arthritis patients who started treatment with/without methotrexate (MTX) (using biologic disease-modifying antirheumatic drugs or Janus kinase inhibitors instead) in Japan.
Methods
Using a Japanese hospital-based administrative claims database, rheumatoid arthritis patients who received treatment [abatacept (ABA), interleukin-6 receptor inhibitor, tumor necrosis factor inhibitor, or Janus kinase inhibitor] between 1 January 2015 and 31 December 2019 were enrolled.
Results
Overall, 19,301 patients were included (10,530 receiving MTX; 8771 not receiving MTX within 60 days of the first treatment). Mean ages at diagnosis were 60.7 and 65.9 years in the MTX and non-MTX groups, respectively (P < .0001). The non-MTX group had higher proportions of patients with Charlson Comorbidity Index ≥1 (P < .0001) and higher comorbidity rates. ABA was the most frequently used drug among patients with infectious/parasitic, circulatory, and respiratory diseases at baseline. Interleukin-6 receptor inhibitor had the highest use rate among patients with neoplasms; blood, gastrointestinal, and genitourinary diseases; and abnormal clinical/laboratory findings. ABA had the highest persistence probability from 6 months onward.
Conclusions
MTX is used less frequently among older Japanese rheumatoid arthritis patients or those with comorbidities. In such patients, ABA is the most frequently used drug, followed by interleukin-6 receptor inhibitor, when MTX is not used at treatment start.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Japan Medical, Innovative Medicine, Bristol Myers Squibb K.K., Tokyo, Japan.
- Real-World-Data Analytics, Bristol Myers Squibb, London, UK.
- Department of Allergy and Rheumatology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
ORCID-Profile: Naohisa Miyakawa
Zitieren
APA
Miyakawa, N., Tsuritani, K., Teixeira, B. C., & Fujio, K. (2024). Disease-modifying antirheumatic drug selection in Japanese patients with rheumatoid arthritis treated with biologics or JAK inhibitors without methotrexate: A retrospective hospital-based administrative claims database study. Modern Rheumatology. https://doi.org/10.1093/mr/roae021
Vancouver
Miyakawa N, Tsuritani K, Teixeira BC, Fujio K. Disease-modifying antirheumatic drug selection in Japanese patients with rheumatoid arthritis treated with biologics or JAK inhibitors without methotrexate: A retrospective hospital-based administrative claims database study. Modern Rheumatology. 2024. doi:10.1093/mr/roae021
BibTeX
@article{Miyakawa2024,
author = {Miyakawa, Naohisa and Tsuritani, Katsuki and Teixeira, Bruno Casaes and Fujio, Keishi},
title = {Disease-modifying antirheumatic drug selection in Japanese patients with rheumatoid arthritis treated with biologics or JAK inhibitors without methotrexate: A retrospective hospital-based administrative claims database study},
journal = {Modern Rheumatology},
year = {2024},
doi = {10.1093/mr/roae021}
}
EUVIMED